Neurocrine Biosciences, Inc (NASDAQ:NBIX) shares, rose in value on Friday, March 28, with the stock price down by -0.74% to the previous day’s close as strong demand from buyers drove the stock to $113.16.
Actively observing the price movement in the last trading, the stock closed the session at $114.00, falling within a range of $112.17 and $113.92. The value of beta (5-year monthly) was 0.353 whereas the PE ratio was 34.38 over 12-month period. Referring to stock’s 52-week performance, its high was $157.98, and the low was $105.18. On the whole, NBIX has fluctuated by -3.70% over the past month.
With the market capitalization of Neurocrine Biosciences, Inc currently standing at about $11.28 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-05.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 2.67B, with a low estimate of 545.47M and a high estimate of 632.09M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 598.05M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NBIX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0.90, with the price of NBIX currently trading nearly 0.99% and -9.26% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.16, while the 7-day volatility ratio is showing 2.24% which for the 30-day chart, stands at 2.52%. Furthermore, Neurocrine Biosciences, Inc (NBIX)’s beta value is 0.32, and its average true range (ATR) is 3.06.
A comparison of Neurocrine Biosciences, Inc (NBIX) with its peers suggests the former has fared considerably weaker in the market. NBIX showed an intraday change of -0.74% in last session, and over the past year, it shrunk by -19.84%%.
Data on historical trading for Neurocrine Biosciences, Inc (NASDAQ:NBIX) indicates that the trading volumes over the past 10 days have averaged 1.09 and over the past 3 months, they’ve averaged 1.29 million. According to company’s latest data on outstanding shares, there are 99.40 million shares outstanding.
Nearly 2.92% of Neurocrine Biosciences, Inc’s shares belong to company insiders and institutional investors own 94.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.29 million shares as on 2025-03-14, resulting in a short ratio of 2.45. According to the data, the short interest in Neurocrine Biosciences, Inc (NBIX) stood at 387.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 3.04 million. The stock has fallen by -17.10% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBIX stock heading into the next quarter.
